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ABSTRACT
Angioedema (AE) is a rare but potentially life-threatening side
effect of therapy with inhibitors of angiotensin-converting en-
zyme (ACE), the main bradykinin (BK)- inactivating metallopep-
tidase in humans. The pathogenesis of ACE inhibitor (ACEi)-
associated AE (AE) is presently unknown, although there is
increasing evidence of a kinin role. We analyzed the metabo-
lism of endogenous BK (B2 receptor agonist) and its active
metabolite, des-Arg9-BK (B1 receptor agonist), in the presence
of an ACEi during in vitro contact activation of plasma from
hypertensive patients (n  39) who presented AE. Kinetic
parameters were compared with those measured in a control
group (AE) of hypertensive patients (n  39) who never man-
ifested any acute or chronic side effects while treated with an
ACEi. The different kinetic parameters were analyzed using a
mathematical model (y  k t e t) previously applied to a
normal, healthy population. The slope of BK degradation, but
not its formation from high-molecular-weight kininogen, was
lower in AE patients when compared with the AE controls.
des-Arg9-BK accumulation during the kinetic measurements
was significantly higher in AE plasma. This accumulation of
the B1 agonist in AE patients paralleled its half-life of degra-
dation. In conclusion, our results show, for the first time, that an
abnormality of endogenous des-Arg9-BK degradation exists in
the plasma of patients with ACEi-associated AE, suggesting
that its pathogenetic mechanism lies in the catabolic site of
kinin metabolism.
Angiotensin-converting enzyme inhibitors (ACEi) have been
used successfully for 20 years in the treatment of different
cardiovascular and metabolic diseases (Unger and Gohlke,
1994). Despite their clinical effectiveness, ACEi have acute side
effects, the symptoms of which vary according to the clinical
context (Blais et al., 2000). Although rare, these side effects are
potentially life-threatening. Anaphylactoid reactions (ARs) in
patients treated with ACEi have been reported during hemodi-
alysis with a negatively charged membrane (Verresen et al.,
1990), and severe hypotensive reactions have been associated
with blood product transfusions or plasma and low-density li-
poprotein apheresis (Owen and Brecher, 1994; Fried et al.,
1996; Cyr et al., 2001a). Angioedema (AE), another side effect
occurring in patients treated with ACEi for hypertension and
heart failure, consists of recurrent self-limiting local swellings
involving subcutaneous tissues and mucosal layers of the upper
airways and bowel. Its reported frequency is apparently similar
to that of AR and severe hypotensive reactions (Israili and Hall,
1992), although the recent OCTAVE study, involving over
25,000 hypertensive patients, has reported an overall AE inci-
dence higher than that currently admitted. In fact, 0.68% of
patients treated with enalapril exhibited an AE episode (Black,
2002). More recently, cases of AE were reported among stroke
victims treated with recombinant tissue-type plasminogen ac-
tivator while concomitantly medicated with an ACEi (Hill et al.,
2000).
The clinical symptoms of AE have been attributed to bra-
dykinin (BK) (Israili and Hall, 1992; Nussberger et al., 1998).
BK is a nonapeptide, the prototype of a family of vasodilator
peptides, the kinins, released from high-molecular-weight
kininogen (HK) during activation of the plasma contact sys-
tem (Bhoola et al., 1992). BK exerts its pharmacological
activities by binding to its B2 receptor before being metabo-
lized by different peptidases (Hall, 1992). The nature of these
peptidases depends on the biological milieu and the patho-
physiological background (Decarie et al., 1996; Erdo¨s and
Skidgel, 1997). In human plasma, we have shown that BK is
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mainly metabolized by three metallopeptidases. Angiotensin-
converting enzyme (ACE) and X-Pro aminopeptidase (amino-
peptidase P; APP) are, respectively, the first and second
inactivating metallopeptidases in importance (Blais et al.,
1999, 2000; Cyr et al., 2001b). A third enzyme, carboxypep-
tidase N (CPN), represents a minor metabolic pathway in the
absence of ACE inhibition. It is responsible for the transfor-
mation of BK into its active metabolite, des-arginine9-brady-
kinin (des-Arg9-BK). This metabolite has a poor affinity for
B2 receptors but interacts with B1 receptors, the synthesis of
which is dramatically increased in experimental models of
inflammation (Marceau et al., 1998). The pharmacological
activities of des-Arg9-BK, similar to those of BK, are short-
lived because of its breakdown by two metallopeptidases
already involved in the inactivation of BK: ACE and APP. In
this case, however, APP represents the main inactivating
pathway in plasma (Cyr et al., 2001b).
Although an increase of plasma BK concentrations during
the acute phase of ACEi-induced AE was reported recently
(Nussberger et al., 1998), the metabolism of endogenous ki-
nins has yet to be documented in these patients.
The objective of the present study was to define the me-
tabolism of endogenous BK and its active metabolite, des-
Arg9-BK, in the plasma of hypertensive patients who pre-
sented with ACEi-associated AE (AE). For this purpose, we
applied to these samples an analytical approach that we
developed recently for a large population of normal, healthy
people (Cyr et al., 2001b). The calculated kinetic parameters
characterizing this metabolism have been compared with
those measured for the plasma of patients who never showed
any acute or chronic ACEi side effects (AE).
Materials and Methods
Patients
Venous blood was obtained from 39 hypertensive patients (20
men, 19 women) who presented with clinically documented AE.
These patients were from the University of Milan (Milan, Italy), the
Academische Ziekenhuis (Leuven, Belgium), and Hoˆpital du Sacre´-
Coeur (Montre´al, QC, Canada). All the patients were white; their age
ranged from 40 to 78 years; and they received enalapril, quinapril,
ramipril, fosinopril, or captopril to treat systemic hypertension. AE
occurred between 1 day and 8 years after the initiation of therapy
and affected the tongue, lips, face, eyelids, and buccal mucosa. At the
time of AE, patients were treated with histamine receptor H1 and H2
blockers, epinephrine, and steroids. At the time of blood sampling
(between 1 and 70 months after AE episodes), ACEi therapy had
been discontinued except in 5 patients who presented recurrent (two
to six) episodes before ACEi therapy was discontinued.
Control plasma was obtained from 39 white hypertensive patients
(with similar mean age and sex proportion) who never developed any
acute (AE, AR, severe hypotensive reactions) or chronic (cough, di-
arrhea or gastrointestinal disturbance, peripheral edema) side ef-
fects while treated with an ACEi. AE patients were from the
University of Milan, the Academische Ziekenhuis, and the Centre
Hospitalier de l’Universite´ de Montre´al (Montre´al, QC, Canada). At
the time of blood sampling, these patients were still treated with an
ACEi. All patients from the different centers were selected according
to the same questionnaire.
Blood Samples
This study was reviewed and approved by the ethics committee for
research on human subjects from the teaching hospitals of the Uni-
versities of Montre´al, Milan, and Leuven, and informed consent was
obtained from all patients.
Twenty milliliters of blood were sampled by venipuncture from the
forearm into tubes containing 0.1 mol/l sodium citrate as anticoag-
ulant (1 volume of sodium citrate to 9 volumes of blood). After
centrifugation (22°C, 15 min, 2500g), the plasma samples were de-
canted and stored at 80°C until biochemical investigation.
Drugs, Peptides, and Reagents.
BK and des-Arg9-BK were acquired from Peninsula Laboratories
(Belmont, CA). The ACEi enalaprilat was obtained from Merck
Frosst Canada (Kirkland, QC, Canada). High-pressure liquid chro-
matography-grade ethanol was obtained from American Chemicals
(Montre´al, QC, Canada).
Metabolism of Endogenous BK and des-Arg9-BK
Contact System Activation. Plasma was activated as described
earlier for normal healthy people (Cyr et al., 2001b). Briefly, 1 ml of
plasma was preincubated with enalaprilat for 20 min at 37°C in
polypropylene tubes at a concentration (130 nM) that totally inhibits
ACE activity. The contact system was then activated by incubation of
the plasma with glass beads (37°C, with agitation). The reaction was
stopped after various incubation periods (0–60 min for BK, and
0–120 min for des-Arg9-BK) by adding cold anhydrous ethanol at a
final concentration of 80% (v/v). The samples were then incubated at
4°C for 1 h and centrifuged (4°C, 15 min, 3000g) for the complete
precipitation of kinin precursors. The supernatant was decanted and
evaporated to dryness in a SpeedVac concentrator (Thermo Savant,
Holbrook, NY). The residues were stored at 80°C until quantifica-
tion of the immunoreactive peptides BK and des-Arg9-BK.
Quantification of BK and des-Arg9-BK
The residues of evaporated ethanolic extracts were resuspended in
50 mM Tris/HCl buffer, pH 7.4, containing 100 mM NaCl and 0.05%
Tween 20. After resuspension, residual BK and formed des-Arg9-BK
were quantified by two specific competitive enzyme immunoassays,
as described previously (Decarie et al., 1994; Raymond et al., 1995).
These methods have been validated and their analytical perfor-
mances reported (Blais et al., 2000).
Mathematical Treatment
The following mathematical model, y  k t e t, t  0, was fitted to
the concentrations of endogenous BK and des-Arg9-BK measured at
different times (t) for each AE and AE subject. This three-parameter
(k, , and ; k  0,  and   0) model corresponds to a form similar to
gamma distribution (Rice, 1995) and has been described and validated
earlier (Cyr et al., 2001b). The  and  parameters are, respectively,
related to the shape of the first and the second part of the curve
corresponding to the formation and the degradation of each peptide.
These  and  parameters allow the calculation of other kinetic param-
eters: time of the maximum, the value of t for which the maximum of
the curve was obtained t  /; maximum, the value of the maximum
of the curve, which corresponds to the value of the curve for t  /;
AUC, the area under the curve, which is mathematically given by k(
 1)/1, where ( 1) is the gamma function; half-life of formation
(tf), the value tf in the interval 0 to / for which t
 et (0.5) (/) e;
half-life of degradation (td), the value td in the interval / to for which
t et  (0.5) (/) e; slope of the half-life of formation, the value of
the slope of the curve at half-life formation  ketf tf
1(  tf); and
slope of the half-life of degradation, the value of the slope of the curve at
half-life degradation: ketd td
1(  td).
Statistical Analysis
The means of the parameters of the two groups (AE and AE)
were compared, using a t test with the Satterwaite-Welch approach
and taking into account the possible heterogeneity of variances
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(Neter et al., 1996). p values less than 0.05 were considered statis-
tically significant.
Results
Plasma Metabolism of Endogenous BK and des-
Arg9-BK from AE and AE Patients. Figure 1 illus-
trates the comparative profiles of the patient means for the
synthesis and degradation of BK and its active metabolite,
des-Arg9-BK, measured during the activation of AE and
AE plasma in the presence of an ACEi, with the mean
reference population profile published earlier (Cyr et al.,
2001b). The mathematical model parallels the actual mea-
sured concentrations and illustrates a clear difference in the
kinetic profiles of the B1 receptor agonist, des-Arg
9-BK, be-
tween AE and AE patients.
For BK, no difference between AE and AE plasma could
be calculated for the different kinetic parameters (, tf, slope)
characterizing the ascending part of the curve. The latter rep-
resents the kinetics of generation of this peptide from HK (Ta-
ble 1). The  parameter and its slope, which reflects the catab-
olism of the B2 agonist by APP and kininase I in the presence of
ACE inhibition, were lower (p  0.022 and p  0.016, respec-
tively) in AE samples compared with the AE control group.
However, no difference could be detected for the maximal con-
centration and total amount of BK formed, as reflected by a
similar AUC during the 60-min observation period.
The main metabolic differences between AE and AE
patients were calculated for des-Arg9-BK. These results (Ta-
ble 1) are illustrated in Figs. 1 and 2. The AUC, reflecting
des-Arg9-BK accumulation during the 120-min incubation
period, was significantly higher in the AE group (p 
0.005). Similarly, a higher maximal concentration of the pep-
tide (p  0.001), which was also delayed in time (p  0.030),
was observed for these patients. These anomalies are related
to an important difference affecting the degradation of the B1
receptor agonist, as reflected in a lower  value (p  0.001)
and a higher half-life of degradation, td (p  0.001), in the
AE group. Although the  value was lower for AE sam-
Fig. 1. Kinetic gamma model-fitted profiles
of formation and degradation of BK (A) and
des-Arg9-BK (B) for mean AE (solid line)
and AE (dashed line) patients after acti-
vation of the contact system, in the pres-
ence of enalaprilat, with glass beads. Dot-
ted lines are values for reference
population. Superscript graphs (a and b)
are actual measured value profiles.
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ples, no significant differences could be measured for the t1/2
of formation and its slope.
Comparison of des-Arg9-BK Metabolism in AE Pa-
tients, AE Patients, and a Reference Population. The
kinetic parameters of des-Arg9-BK metabolism were differ-
ent for AE and AE plasma and have been compared with
the mean values calculated earlier for the reference popula-
tion. As illustrated in Fig. 2, significantly higher values in
AE samples were calculated for the AUC (p  0.030), for
the maximal concentration of peptide generated (p  0.008),
and the td half-life of degradation (p  0.036). The  value
was significantly lower in AE samples (p  0.004). For the
same parameters in AE patients, significantly lower values
were calculated for the AUC (p  0.012) and the half-life of
degradation td (p  0.032). The  value was significantly
higher (p  0.039). No significant difference with the refer-
ence population could be calculated for the various kinetic
parameters characterizing des-Arg9-BK formation in the
AE and AE groups.
Influence of the Time of AE Occurrence and the
Time of Blood Sampling. The influence of the time interval
between the start of medication and the AE episode on the
kinetic parameters characterizing des-Arg9-BK metabolism
in the AE group was considered at three levels: 1 month or
less, 1 year or less, and more than 1 year. One-way analysis
of variance did not allow the measurement of significant
differences in  values among these three time intervals.
Similarly, we could not measure a significant effect of the
time between AE and blood sampling (1 year or less, 2 years
or less, or more than 2 years).
Discussion
In this article, we provide evidence, for the first time, of an
anomaly affecting the degradation of endogenous kinins,
mainly of des-Arg9-BK, in the plasma of patients who pre-
sented ACEi-associated AE. These results must be discussed
in light of our previous observations on the same patients,
showing a significant decrease of APP activity, but no differ-
ence of CPN activity in AE patients when compared with
the AE control group and the reference population (Adam
et al., 2002).
The experimental approach used in this paper has been de-
veloped recently in our laboratory and validated by application
to a large number of normal, healthy people (Cyr et al., 2001b).
It uses glass beads, a well known activator of the plasma con-
tact system (Kaplan et al., 1998). The kinetic studies in AE
and AE groups of plasma were performed in the presence of
an ACEi to mimic what would happen in vivo in the plasma of
patients treated with such a drug. ACEi also increases the
transformation of BK into des-Arg9-BK, which otherwise rep-
resents a minor metabolic pathway in humans (Decarie et al.,
1996; Cyr et al., 2001b). We assessed the pharmacokinetic char-
acteristics of this activation. The release and the degradation of
endogenous BK and des-Arg9-BK formed during the activation
process have been measured, using highly sensitive and specific
immunoassays developed in our laboratory (Decarie et al., 1994;
Raymond et al., 1995). These assays employ highly specific
antibodies to the carboxy-terminal end of both peptides, which
is responsible for B2 (BK) and B1 (des-Arg
9-BK) pharmacologi-
cal activity, respectively.
Under our experimental conditions, we did not find evidence
of any abnormality in the formation of BK from HK. In fact, the
, tf, and slope of the tf parameters, the values of which are
related to formation of the peptide, were similar in both AE
and AE plasma. These observations argue against a quanti-
tative or qualitative defect in one of the constituents of the
contact system (Factor XII, prokallikrein, or HK). Also unlikely
is a defect of antiproteases responsible for the control of this
system, even though quantitative or qualitative defects of C1
esterase inhibitor have been associated with hereditary angio-
neurotic edema (Agostoni and Cicardi, 1992).
The degradation of BK in the presence of an ACEi, how-
TABLE 1
Parameters characterizing the gamma model fitted to endogenous measurements of kinins
Data represent means  S.D.
Parameter
BK (n  39) des-Arg9-BK (n  39)
AE AE AE AE
 0.94  0.53 0.75  0.31 0.85  0.35 0.62  0.33
p  0.055 p  0.004
Slope of the t1/2 of formation 22,992  7,572 27,105  31,838 2.65 E10  1.65 E11 5.48 E7  3.17 E8
p  0.435 p  0.325
t1/2 of formation (min) 0.86  0.29 0.82  0.49 2.32  1.26 2.61  2.47
p  0.725 p  0.526
Maximum (nM) 500  138 510  207 131  56 231  165
p  0.809 p  0.001
Time of maximum (min) 4.2  0.8 6.1  8.1 12.1  6.6 16.9  11.3
p  0.152 p  0.030
 0.24  0.17 0.16  0.08 0.08  0.04 0.05  0.03
p  0.022 p  0.001
Slope of the t1/2 of degradation 3,877  2,117 2,825  1,604 293  143 309  298
p  0.016 p  0.755
t1/2 of degradation (min) 12.2  2.7 25.2  61.8 36.9  23.5 59.6  34.7
p  0.191 p  0.001
AUC (pmol/ml 60 min or 120 min) 6,305  2,247 16,175  48,333 5,660  5,214 1.64 E6  2.26 E6
p  0.207 p  0.005
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ever, is statistically slower in AE than in AE control
patients. Despite significant p values, these differences are
not sufficient to lead to an increased concentration of BK
during the activation period. Our observations may be ex-
plained by the fact that even in the presence of a decreased
activity of APP and ACE inhibition, BK is still transformed
into des-Arg9-BK by CPN.
The accumulation of des-Arg9-BK, as assessed by the AUC,
is significantly higher in AE when compared with AE
plasmas. As CPN activities are similar in both groups of
samples, this increase of B1 agonist concentration is a con-
sequence of a decrease of its metabolism by APP, a pivotal
degrading enzyme in the presence of an ACEi (Adam et al.,
2002). Contrary to our observations with BK, the differences
affecting inactivation of the B1 agonist are strongly signifi-
cant, as reflected by the p values near and below 0.001 for 
and the half-life of degradation (td). These strong differences
explain the much more pronounced accumulation of des-
Arg9-BK during the activation of AE plasma.
Our in vitro observations are physiologically relevant. In fact,
we have previously evidenced in vivo that an accumulation of
immunoreactive des-Arg9-BK parallels a proinflammatory ef-
fect mediated by the B1 receptors (Blais et al., 1997). Although
the pharmacological role of B1 agonist and its receptors has
been characterized in different experimental models, such a
role in human pathology has been poorly defined (Marceau et
al., 1998). We have, however, recently described an anomaly in
the degradation of exogenous des-Arg9-BK added to the plasma
Fig. 2. Panels representing des-Arg9-BK area under the curve (panel A), des-Arg9-BK  values (panel B), des-Arg9-BK maximal concentration (panel
C), and des-Arg9-BK td value (panel D). Values measured in AE and AE patients (n  39), both compared with the reference population value (n
 109), are shown. Box plots display summary statistics for the distribution. The lower boundary of the box is the 25th percentile and the upper
boundary is the 75th percentile. The line in the box represents the median. The largest and smallest values that are not outliers are also shown. Lines
are drawn from the ends of the box to these values. , p  0.05; , p  0.01; , p  0.001.
236 Molinaro et al.







of patients who presented an AR while treated with an ACEi
and dialyzed with a negatively charged membrane (Blais et al.,
1999). It is well known that these dialyzed patients are chron-
ically inflamed and exhibit high concentrations of blood proin-
flammatory cytokines, well known to induce the B1 receptor in
animals (Pertosa et al., 2000). Although both B1 and B2 kinin
receptor subtypes exhibit some structural homology, similar
signaling pathways and similar pharmacological consequences,
functional responses show two main differences (Faussner et
al., 1999). On the one hand, B1 receptors are inducible, whereas
B2 receptors are constitutively present. On the other hand,
some evidence now exists for an agonist-induced temporary
desensitization of B2 receptors involving receptor phosphoryla-
tion and endocytosis (Blaukat et al., 1996; Faussner et al.,
1999). Furthermore, some recent evidence suggests that chronic
ACE inhibition itself induces functional vascular and renal B1
receptor expression, possibly involving homologous up-regula-
tion (Marin-Castano et al., 2002). Another group has also re-
ported that enalaprilat and other ACEi could directly activate
human B1 receptors, even in the absence of an exogenous B1
receptor agonist (Ignjatovic et al., 2002). In this case, however,
the presence of endogenous kinin was not documented.
As plasma BK has been previously shown to be increased
during the acute episode of AE (Nussberger et al., 1998), this
peptide could initiate the inflammatory process via the B2 re-
ceptor, thereafter relayed by des-Arg9-BK and stimulating its
B1 receptor. These findings do not mean that des-Arg
9-BK is
necessarily the only mediator of AE. In fact, some pharmaco-
logical evidence suggests that kinins could lead to the local
release of neurokinins, particularly the sensory neuropeptide
substance P (Ferreira et al., 2000). Interestingly, in this regard,
a decrease in dipeptidyl peptidase IV activity, a substance P-
degrading enzyme, was also reported in a limited number of
hypertensive patients during ACEi-associated AE (Lefebvre et
al., 2002). Thus, a multifactorial nature of ACEi-associated AE
is expected and could explain its rarity. This side effect results
from the gathering of at least three different factors: pharma-
cological (ACEi treatment), metabolic, and triggering factors.
Our data clearly show an anomaly in the degradation of endog-
enous des-Arg9-BK in the plasma of patients with ACEi-asso-
ciated AE, suggesting that its pathogenetic mechanism lies in
the catabolic site of kinin metabolism. However, the triggering
factors responsible for in vivo kinin release remain to be de-
fined. In this regard, recently reported AE associated with re-
combinant tissue-type plasminogen activator used in stroke
(Francis et al., 1991; Hill et al., 2000), with its capacity to
activate the kinin-forming cascade in vitro (Molinaro et al.,
2002), could bring new insights.
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